Biotech Specialty Pharma

Biovista, Inc.

2421 Ivy Road
Charlottesville, VA 22903 United States
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Repurposing drugs for unmet clinical needs.

Management Andreas Persidis Ph.D., CEO, Co-Founder; Aris Persidis Ph.D, President, Co-Founder; Graham Anthony, MBA, CFO

Click here for Financial Data
Keywords: KIP2018, ocular, opthalmology, diabetes, obesity, CNS, oncology

Comment


Updated: Jan. 24, 2018


Description

Biovista Inc. is dedicated to maximizing the value of research and clinical development by systematically repurposing drugs for unmet and commercially valuable medical needs. Biovista's proprietary di......view more

Products / Services

Pro-active Lifecycle Extension: Biovista helps companies find new uses for their existing drugs--both for marketed drugs & pre-clinical drugs as well as finding new uses for safe drugs that didn't mee......view more

Technology / Differentiation

Biovista's proprietary discovery platform, the Clinical Outcome Search Space, matches a deep multi-dimensional description of the mechanism of action (MoA) of 90,000 drugs & compounds against the MoAs...view more

Market / Customers

The FDA currently licenses Biovista's technology to predict potential severe adverse events for drugs entering the Clinic. Biovista is currently negotiating agreements with 3 of the top 10 Pharma f......view more


Status

As Biovista's candidates have been proven safe in prior use, Biovista believes its two MS and one epilepsy candidates can enter the clinic at the Phase IIa level for proving efficacy in man. To dat...view more

Analyst Coverage